

China Life (2628 HK)

4Q net profit could decline despite better capital market

BUY (Maintain)

Target Price HK\$20.00
Up/Downside 38.1%
Current Price HK\$14.48

China Insurance

Nika MA

(852) 3900 0805
 nikama@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	1,448.0
Avg 3 mths t/o (HK\$ mn)	815.9
52w High/Low (HK\$)	20.55/8.77
Total Issued Shares (mn)	100.0

Source: FactSet

Shareholding Structure

Citigroup Inc.	6.0%
BlackRock, Inc.	5.9%


Source: HKEx

Share Performance

	Absolute	Relative
1-mth	-2.6%	-2.4%
3-mth	-13.9%	-12.1%
6-mth	35.1%	16.5%

Source: FactSet

12-mth Price Performance



Source: FactSet

Auditor: Ernst & Young

Related reports:

- China Life (2628 HK) - 3Q NPAT boosted by net fair value gains; expect resilient full-year NBV upswing, 5 Nov, 2024 ([link](#))
- China Life (2628 HK) - Strong lift in banca NBV margin; investment income may continue to rebound in 2H24M, Sep 2, 2024 ([link](#))
- China Life (2628 HK) - Highest VNB growth in years; net profit decline narrowed on track, May 2, 2024 ([link](#))
- China Life (2628 HK) - 4Q net loss markedly narrowed; VNB grew in low-teens despite revised EV assumptions, Apr 8, 2024 ([link](#))
- China Life (2628 HK) - 3Q NP dragged by investment setbacks; first-in -sector steady agent scale props up 2024 NBV, Oct 31, 2023 ([link](#))
- China Life (2628 HK) - Outpaced VNB growth in 1H23; short-term NP pushback not affect value growth, Aug 25, 2023 ([link](#))

China Life released prelim. earnings alert. The company expects net profit to grow 122%-144% YoY (or at RMB56.2-66.4bn) under IFRS and 100%-120% YoY (or at RMB 51.2-61.4bn) under China Accounting Standards (ASBE) in FY24, easing from the increase of 174% in year-to-3Q24. 4Q bottom-line could range from a net loss of RMB 2.16bn to a gain of RMB 8.08bn, implying at most 0.8% YoY increase vs RMB8.02bn in 4Q23. We attribute this more-than-doubled net profit primarily to the equity market rally in 3Q, which surged the insurer's total investment income by +152.4% YoY in 9M24. Given better capital market as CSI300 down 2% in 4Q24 (vs 4Q23: -7%) and 10yr CGB yield down below 1.7% by end-FY24 (vs FY23: 2.56%), **we think this potential 4Q net profit decline could result from investment volatilities, as the insurer continues fine-tuning its strategic asset allocation (SAA) structure** by increasing HDY stocks under FVOCI, and balancing equity exposure to FVTPL and FVOCI, in our view. By 1H24, core equities (incl. stocks and equity funds) under FVTPL and stocks under FVOCI made up 11.2%/0.6% of total investment assets. Considering investment fluctuations, we revise FY24E/25E/26E EPS forecasts to RMB 3.85/2.68/2.81 (vs previous: 4.45/2.58/2.61, implying changes as of -14%/4%/8%). **We expect FY24/25E NBV to grow by 19.2%/9.2%, with TP unchanged at HK\$20.0. Maintain BUY.**

■ **4Q net profit could decline YoY due to investment volatilities.** The insurer's FY24 net profit ranges at RMB102.4bn-112.6bn, implying 122%-144% earnings growth (or at RMB56.2-66.4bn) based on IFRS; and 100%-120% YoY increase (or at RMB 51.2-61.4bn) based on ASBE. Net profit in year-to-3Q24 edged up 174% YoY to RMB104.5bn, thanks to the beta-driven equity market rally that boosted the net fair value gains by 80.1x/73.3x YoY to RMB 147.7bn/99.9bn in 9M/3Q24. **We stated in our last report ([link](#)) that such soaring investment income may not be sustainable, and the insurer should have addressed more on steady growth of net investment income over the long run.** 4Q bottom-line results from a net loss of RMB2.16bn to a net gain of RMB 8.08bn, suggesting at most 0.8% YoY increase (vs 4Q23: RMB 8.02bn). We attribute this potential 4Q net profit decline to investment volatilities given 1) higher-than-most listed peers' exposure to FVTPL core equities, comprising 11.2% of total investment assets by 1H24 (second highest after NCI: 16.3%); and 2) the majority of bond investments (83%) were assigned to FVOCI, which might lag on seizing the fair value gains from a bullish bond market amid descending interest rates in 2H24 (10YR CNGB yield down more than 80bps to <1.7% by end-FY24), in our view.

■ **Expect resilient NBV growth by 19%/9% in FY24/FY25E.** Total premium grew 4.7% YoY to RMB 671.7bn in FY24, with quarterly premium increases by 3.2%/6.3%/9.3%/1.1% YoY in 1Q/2Q/3Q/4Q24. We expect to see resilient NBV growth by 19%/9% YoY in FY24/25, bolstered by continued margin expansion.

■ **Valuation:** The stock is trading at 0.24x FY25E P/EV and 0.67x FY25E P/BV with annualized ROE at 21% in FY24E, as we estimate. On dividends front, we project China Life will increase DPS but may not be as much as earnings growth as net fair value gains are unsustainable to transfer into direct S/H gains. Considering investment fluctuations, **we adjust FY24/25/26E EPS forecasts to RMB3.85/2.68/2.81 (previous RMB4.45/2.58/2.61, implying changes of -14%/4%/8%).** Maintain BUY, with TP at HK\$20.0, indicating 0.4x FY25E P/EV.

Earnings Summary

(YE 31 Dec)	FY22A	FY23A	FY24E	FY25E	FY26E
Net profit (RMB mn)	68,112	47,547	99,578	100,814	104,799
EPS (Reported)(RMB)	2.36	1.63	3.85	2.68	2.81
Consensus EPS (RMB)	n.a	n.a	3.88	2.73	2.92
P/B (x)	1.0	0.8	0.7	0.7	0.7
P/Embedded value (x)	0.3	0.3	0.3	0.2	0.2
Dividend yield (%)	3.6	3.2	8.6	6.0	6.3
ROE (%)	17.3	9.7	21.1	13.5	13.8

Source: Company data, Bloomberg, CMBIGM estimates | Note: (1) stock price quoted by market close on 24 Jan 2025; (2) dividends peg to net profit attributable to shareholder with assumed 30% payout.

Financial Summary

INCOME STATEMENT	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Insurance revenue		182,578	212,445	240,632	246,018	252,587
Insurance service expenses		(131,614)	(150,353)	(178,243)	(182,148)	(186,923)
Net expenses from reinsurance contracts held		2,155	(288)	(292)	(778)	(1,290)
Insurance service results		53,119	61,804	62,098	63,092	64,374
Net finance (expenses)/income from insurance contracts		(148,700)	(127,923)	(218,211)	(106,943)	(120,813)
Net finance (expenses)/income from reinsurance contracts		583	616	336	0	0
Interest income		0	122,994	123,806	129,913	145,444
Net investment income		175,360	(9,375)	166,391	7,505	9,869
Credit impairment losses		(3,150)	1,217	316	348	382
Net investment results		24,093	(12,471)	72,638	30,823	34,883
Other income		8,944	10,603	12,563	13,191	13,850
Other expenses		(15,212)	(18,131)	(18,318)	(19,234)	(20,195)
Other results		(11,131)	(12,836)	(11,170)	(11,999)	(12,897)
Profit before tax		70,060	44,576	132,376	90,814	95,347
Income taxes		(1,948)	2,971	(21,519)	(13,622)	(14,302)
Net profit		68,112	47,547	110,857	77,192	81,045
Net profit attributable to shareholders		66,680	46,181	108,683	75,678	79,455

BALANCE SHEET	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
ASSETS						
Cash and amount due from banks and other financial institutions	542,403	524,100	433,014	529,026	595,157	663,257
Balances with central bank and statutory deposits	6,333	6,333	6,520	12,224	13,752	15,326
Investments in associates and joint ventures	258,933	262,488	258,760	261,348	263,961	266,601
Property	58,150	56,369	55,190	55,122	55,055	54,989
Investment property	13,374	13,193	12,753	13,318	14,983	16,697
Reinsurance contract assets	19,327	24,096	25,846	27,716	31,371	35,421
Financial investments:	3,599,689	3,878,185	4,798,898	5,461,473	6,144,188	6,847,228
At amortized cost:	0	0	211,349	200,551	225,621	251,437
At fair value through other comprehensive income:	0	0	2,882,174	3,324,235	3,739,783	4,167,702
At fair value through profit or loss:	0	0	1,705,375	1,936,688	2,178,785	2,428,089
Deferred tax assets	24,180	46,126	24,431	29,311	35,166	42,191
Other assets	82,519	71,584	37,369	44,285	63,773	295,184
Cash and cash equivalents	60,459	127,594	149,305	93,609	105,311	117,361
Total assets	4,665,367	5,010,068	5,802,086	6,527,432	7,322,717	8,354,254
LIABILITIES						
Insurance contract liabilities	3,809,716	4,266,947	4,859,175	5,656,592	6,402,544	7,229,191
Borrowings	19,222	12,774	12,857	12,460	12,075	11,703
Obligations under repurchase agreements	239,446	148,958	216,851	117,685	63,868	34,661
Deferred tax liabilities	999	272	0	0	0	0
Current tax liabilities	248	238	309	245	194	154
Bonds payable	34,994	34,997	36,166	0	0	0
Other liabilities	164,095	170,749	189,506	178,607	264,428	484,321
Total liabilities	4,268,874	4,635,095	5,315,052	5,965,589	6,743,109	7,760,029
EQUITIES						
Share capital	28,265	28,265	28,265	28,265	28,265	28,265
Reserves	156,677	99,033	145,933	150,321	118,578	75,604
Retained profits	203,478	238,723	302,895	372,587	421,313	478,064
Total shareholders' equity	388,420	366,021	477,093	551,173	568,156	581,933
Non-controlling interests	8,073	8,952	9,941	10,670	11,452	12,292
Total equity	396,493	374,973	487,034	561,843	579,608	594,225
Total liabilities & equity	4,665,367	5,010,068	5,802,086	6,527,432	7,322,717	8,354,254

PER SHARE DATA	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
DPS	0.65	0.49	0.43	1.15	0.80	0.84
EPS (Reported)	1.80	2.36	1.63	3.85	2.68	2.81
Consensus EPS	n.a	n.a	n.a	3.88	2.73	2.92
Group embedded value/share	42.6	43.5	44.6	51.4	55.2	59.5
VNB/share	1.58	1.27	1.45	1.56	1.70	1.84
No. of shares outstanding (basic)	28,265	28,265	28,265	28,265	28,265	28,265
PROFITABILITY	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Return on equity (ROE)	10.9%	17.3%	9.7%	21.1%	13.5%	13.8%
VNB margin (FYP APE basis)	n.a	17.8%	17.5%	21.3%	21.9%	22.4%
VALUATION	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
P/Embedded value (x)	0.3	0.3	0.3	0.3	0.2	0.2
P/B (x)	0.8	1.0	0.8	0.7	0.7	0.7
Dividend yield (%)	4.8	3.6	3.2	8.6*	6.0	6.3

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets. | Note: (1) stock price by market close on 24 Jan, 2025; (2) dividends peg to the insurer's net profit attributable to shareholders with assumed 30% payout ratio.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.